| __timestamp | MiMedx Group, Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 90480000 | 504755000 |
| Thursday, January 1, 2015 | 133384000 | 838526000 |
| Friday, January 1, 2016 | 179997000 | 1177697000 |
| Sunday, January 1, 2017 | 220119000 | 1320433000 |
| Monday, January 1, 2018 | 258528000 | 1556200000 |
| Tuesday, January 1, 2019 | 198205000 | 1834800000 |
| Wednesday, January 1, 2020 | 181022000 | 1346000000 |
| Friday, January 1, 2021 | 198359000 | 1824900000 |
| Saturday, January 1, 2022 | 208789000 | 2115900000 |
| Sunday, January 1, 2023 | 211124000 | 2631300000 |
| Monday, January 1, 2024 | 2954400000 |
Unleashing insights
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Regeneron Pharmaceuticals, Inc. and MiMedx Group, Inc. over the past decade. From 2014 to 2023, Regeneron consistently outpaced MiMedx in SG&A spending, reflecting its expansive operational scale. In 2023, Regeneron's SG&A expenses surged to approximately 2.63 billion, marking a 420% increase from 2014. In contrast, MiMedx's expenses grew by 133% over the same period, reaching around 211 million. This disparity highlights Regeneron's aggressive market strategies and broader operational footprint. As the pharmaceutical landscape continues to shift, these financial insights offer a glimpse into the strategic priorities of these industry giants.
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc.
Regeneron Pharmaceuticals, Inc. and Walgreens Boots Alliance, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Alpine Immune Sciences, Inc.
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Pharming Group N.V.
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Grifols, S.A.
Regeneron Pharmaceuticals, Inc. vs PTC Therapeutics, Inc.: SG&A Expense Trends
Regeneron Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Viking Therapeutics, Inc. or MiMedx Group, Inc.
Cost Management Insights: SG&A Expenses for Rhythm Pharmaceuticals, Inc. and MiMedx Group, Inc.
Cost Management Insights: SG&A Expenses for Ligand Pharmaceuticals Incorporated and MiMedx Group, Inc.
Who Optimizes SG&A Costs Better? Wave Life Sciences Ltd. or MiMedx Group, Inc.
Cost Management Insights: SG&A Expenses for Celldex Therapeutics, Inc. and MiMedx Group, Inc.